Barclays Cuts Sotera Health (NASDAQ:SHC) Price Target to $17.00

Sotera Health (NASDAQ:SHC) had its price target lowered by Barclays from $18.00 to $17.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research firms have also recently commented on SHC. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research report on Thursday, November 21st. Citigroup increased their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Sotera Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.08.

Sotera Health Trading Down 0.8 %

NASDAQ:SHC opened at $13.52 on Tuesday. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The firm has a 50 day moving average of $13.45 and a 200 day moving average of $14.56. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of 54.08 and a beta of 1.91.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Darsana Capital Partners LP increased its stake in shares of Sotera Health by 716.9% in the third quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock worth $334,167,000 after acquiring an additional 17,560,636 shares during the period. Sculptor Capital LP acquired a new stake in shares of Sotera Health in the fourth quarter worth $68,400,000. Two Seas Capital LP increased its stake in shares of Sotera Health by 624.0% in the fourth quarter. Two Seas Capital LP now owns 2,896,136 shares of the company’s stock worth $39,619,000 after acquiring an additional 2,496,136 shares during the period. Sessa Capital IM L.P. increased its stake in shares of Sotera Health by 46.5% in the third quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock worth $105,220,000 after acquiring an additional 2,000,000 shares during the period. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Sotera Health by 140.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company’s stock worth $35,907,000 after acquiring an additional 1,534,666 shares during the period. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.